FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308183942> ?p ?o ?g. }

• W4308183942 endingPage "205435812211306" @default.
• W4308183942 startingPage "205435812211306" @default.
• W4308183942 abstract "Background: Iron deficiency is common in chronic kidney disease (CKD) patients not on dialysis (ND). Restoring depleted iron stores through intravenous (IV) route is faster and associated with less side effects. There is conflicting data regarding intravenous iron use and its impact on clinical outcomes in this population. Objective: This study aims at evaluating any negative clinical impact associated with IV iron use in CKD patients at stages (3-5) before dialysis. Design: Retrospective chart review. Setting and Population: Chart analysis of ND CKD 3-5 (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m 2 ) patients who received IV iron between January 2013 and January 2018 in 3 major hospitals in Kuwait. Methods: Outcomes analyzed were rates of all-cause hospitalizations, infection-related hospitalizations, mortality rates, and eGFR decline over 12 months after IV iron infusion in this population divided into 3 groups according to CKD stage. Results: A total of 738 patients were included in our analysis. Mean initial hemoglobin concentration was 111.5 ± 15.0 g/L in group 1 (CKD 3: eGFR 30-59 mL/min/1.73 m 2 ), 103.6 ± 17.7 g/L in group 2 (CKD 4: eGFR 15-29 mL/min/1.73 m 2 ), and 99.4 ± 14.5 g/L in group 3 (CKD 5: eGFR < 15 mL/min/1.73 m 2 but not on dialysis). All-cause hospitalization and infection-related hospitalization were more common among group 3 subjects (adjusted odds ratio =2.12 [95% confidence interval, CI: 1.32-3.41] and 2.02 [95% CI: 1.15-3.55]), respectively. No deaths occurred during 12 months of follow-up. Limitations: Lack of control group, retrospective study. Conclusion: Intravenous iron use in CKD 3-5 ND is generally safe. Higher hospitalization rates in patients with eGFR <30 mL/min are possibly associated with lower baseline hemoglobin, lower baseline eGFR, and higher comorbidity burden, and not related to iron infusion." @default.
• W4308183942 created "2022-11-09" @default.
• W4308183942 creator A5006251988 @default.
• W4308183942 creator A5019511424 @default.
• W4308183942 creator A5024890968 @default.
• W4308183942 creator A5027172780 @default.
• W4308183942 creator A5032848542 @default.
• W4308183942 creator A5034241908 @default.
• W4308183942 creator A5036304365 @default.
• W4308183942 creator A5064929076 @default.
• W4308183942 creator A5069474521 @default.
• W4308183942 creator A5082676713 @default.
• W4308183942 date "2022-01-01" @default.
• W4308183942 modified "2023-09-26" @default.
• W4308183942 title "Safety of Intravenous Iron in CKD Stage 3-5 Patients Not on Dialysis: A Retrospective Cohort Study" @default.
• W4308183942 cites W1571358690 @default.
• W4308183942 cites W1858532931 @default.
• W4308183942 cites W1964685535 @default.
• W4308183942 cites W2009114872 @default.
• W4308183942 cites W2027540835 @default.
• W4308183942 cites W2046551865 @default.
• W4308183942 cites W2046891288 @default.
• W4308183942 cites W2077022855 @default.
• W4308183942 cites W2085784457 @default.
• W4308183942 cites W2097342573 @default.
• W4308183942 cites W2098124630 @default.
• W4308183942 cites W2116948290 @default.
• W4308183942 cites W2138609117 @default.
• W4308183942 cites W2143988248 @default.
• W4308183942 cites W2147294950 @default.
• W4308183942 cites W2186642052 @default.
• W4308183942 cites W2301182697 @default.
• W4308183942 cites W2580449060 @default.
• W4308183942 cites W2772223565 @default.
• W4308183942 cites W2773387077 @default.
• W4308183942 cites W3014325832 @default.
• W4308183942 cites W3101661038 @default.
• W4308183942 cites W65817400 @default.
• W4308183942 doi "https://doi.org/10.1177/20543581221130685" @default.
• W4308183942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36325260" @default.
• W4308183942 hasPublicationYear "2022" @default.
• W4308183942 type Work @default.
• W4308183942 citedByCount "0" @default.
• W4308183942 crossrefType "journal-article" @default.
• W4308183942 hasAuthorship W4308183942A5006251988 @default.
• W4308183942 hasAuthorship W4308183942A5019511424 @default.
• W4308183942 hasAuthorship W4308183942A5024890968 @default.
• W4308183942 hasAuthorship W4308183942A5027172780 @default.
• W4308183942 hasAuthorship W4308183942A5032848542 @default.
• W4308183942 hasAuthorship W4308183942A5034241908 @default.
• W4308183942 hasAuthorship W4308183942A5036304365 @default.
• W4308183942 hasAuthorship W4308183942A5064929076 @default.
• W4308183942 hasAuthorship W4308183942A5069474521 @default.
• W4308183942 hasAuthorship W4308183942A5082676713 @default.
• W4308183942 hasBestOaLocation W43081839421 @default.
• W4308183942 hasConcept C126322002 @default.
• W4308183942 hasConcept C141071460 @default.
• W4308183942 hasConcept C156957248 @default.
• W4308183942 hasConcept C159641895 @default.
• W4308183942 hasConcept C167135981 @default.
• W4308183942 hasConcept C2777417653 @default.
• W4308183942 hasConcept C2778248108 @default.
• W4308183942 hasConcept C2778653478 @default.
• W4308183942 hasConcept C2779978075 @default.
• W4308183942 hasConcept C2908647359 @default.
• W4308183942 hasConcept C3020614022 @default.
• W4308183942 hasConcept C44249647 @default.
• W4308183942 hasConcept C71924100 @default.
• W4308183942 hasConcept C99454951 @default.
• W4308183942 hasConceptScore W4308183942C126322002 @default.
• W4308183942 hasConceptScore W4308183942C141071460 @default.
• W4308183942 hasConceptScore W4308183942C156957248 @default.
• W4308183942 hasConceptScore W4308183942C159641895 @default.
• W4308183942 hasConceptScore W4308183942C167135981 @default.
• W4308183942 hasConceptScore W4308183942C2777417653 @default.
• W4308183942 hasConceptScore W4308183942C2778248108 @default.
• W4308183942 hasConceptScore W4308183942C2778653478 @default.
• W4308183942 hasConceptScore W4308183942C2779978075 @default.
• W4308183942 hasConceptScore W4308183942C2908647359 @default.
• W4308183942 hasConceptScore W4308183942C3020614022 @default.
• W4308183942 hasConceptScore W4308183942C44249647 @default.
• W4308183942 hasConceptScore W4308183942C71924100 @default.
• W4308183942 hasConceptScore W4308183942C99454951 @default.
• W4308183942 hasLocation W43081839421 @default.
• W4308183942 hasLocation W43081839422 @default.
• W4308183942 hasLocation W43081839423 @default.
• W4308183942 hasOpenAccess W4308183942 @default.
• W4308183942 hasPrimaryLocation W43081839421 @default.
• W4308183942 hasRelatedWork W202168480 @default.
• W4308183942 hasRelatedWork W2078800480 @default.
• W4308183942 hasRelatedWork W2152354994 @default.
• W4308183942 hasRelatedWork W2188892098 @default.
• W4308183942 hasRelatedWork W2567256464 @default.
• W4308183942 hasRelatedWork W2810452307 @default.
• W4308183942 hasRelatedWork W2947318399 @default.
• W4308183942 hasRelatedWork W4232865023 @default.
• W4308183942 hasRelatedWork W4297448048 @default.
• W4308183942 hasRelatedWork W4365511089 @default.

• next